PuHua Neuro Alliance Partners with Biotop Bio to Advance Medical Research in Private Healthcare

Tiantan Puhua Hospital

Recently, Puhua Brain Alliance and 100Biotech signed a strategic cooperation agreement in Beijing. In the future, both parties will conduct high-level medical scientific research in fields such as neurology and neurosurgery, working together to contribute to overcoming medical challenges in these areas.

Puhua Brain Science Alliance is a medical technology management platform invested by Bain Capital of the United States. It is dedicated to providing technical services in neurology, neurosurgery, interventional procedures, rehabilitation, and oncology. Leveraging its own hospital under the Asia Pacific Medical Group controlled by Bain Capital (Beijing Tiantan Puhua Hospital) as well as partner hospitals, and combining rich operational management experience with unique and innovative medical technologies, it engages in diversified cooperation with local hospitals and physicians in areas such as academics, technology, operational management, finance, and acquisitions.

Founded in 2010, 100Biotech is the first company in China to provide medical research consulting and technical services to clinicians. Its founder, Dr. Guo Lei, proposed a new, highly efficient research model—Research 5.0.

“Research 5.0,” a novel research paradigm, has helped over 5,000 clinicians overcome scientific research challenges and has gained widespread recognition among physicians. Dr. Guo Lei believes that the Research 5.0 model is an efficient innovation-driven approach to scientific research, powered by management and connectivity thinking in the new era. Through this collaboration with PwC, we aim to promote the concepts and methodologies of strategic research management, research team management, and research time management.

Medicine is a profession that demands lifelong learning, and a key indicator of an excellent medical institution is its academic and research capabilities. The strategic research collaboration established between 100Biotech and the Puhua Brain Health Alliance underscores their mutual commitment to advancing scientific research.

The Puhua Brain Science Alliance Medical Management Platform is currently composed primarily of senior-level experts, including 80 core chief physicians and 104 associate chief physicians, all hailing from renowned tertiary Grade A medical institutions. This collaboration transcends short-term interests or developmental goals; it is poised to establish core professional value and reputation within the specialized field. By leveraging this strategic alliance of leading experts, we aim to advance medical research, tackle complex medical challenges, and ultimately translate these achievements into clinical applications to benefit patients.

Dr. Guo Lei, Founder of 100Biotech

Dr. Guo Lei pointed out: “Huawei has become what it is today because of its dedicated efforts to strengthen basic research and innovation, investing 30% of its total revenue in scientific research. Through long-term hard work, it has built a robust knowledge system that cannot be easily matched by competitors. The same applies to the healthcare sector. Leading medical institutions, such as the Mayo Clinic, place great emphasis on academic and scientific research, which enables them to maintain their authoritative industry position and attract top-tier medical talent.”

Currently, private medical institutions in China have recognized the importance of scientific research for the long-term development of the healthcare industry. By positioning themselves with high-level academic aspirations and collaborating with professional medical research consulting and technical service providers such as 100Biotech, they can integrate high-end industry resources to establish unique competitiveness and influence in specific fields. This approach will undoubtedly secure greater recognition and unlock future development opportunities on a higher platform.